Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs
Key Highlights
- ➤Vistagen (VTGN) selects GATC Health’s predictive AI for lead clinical-stage programs
- ➤Fasedienol program may use insights for a potential next Phase 3 social anxiety study
- ➤Iruvone may receive predictive modeling support for potential Phase 2 depression studies
- ➤Refisolone may receive predictive modeling support for potential Phase 2 menopausal hot-flash studies
- ➤Collaboration targets protocol development, pipeline prioritization, and resource allocation
Expert Statements
Shawn Singh, President and Chief Executive Officer of Vistagen
“GATC Health’s predictive, purpose-built AI technology and methods are powerful and designed to model complex biological interactions that impact drug development, including potential efficacy and safety”
Shawn Singh, President and Chief Executive Officer of Vistagen
“We are incorporating key predictive insights from our collaboration with GATC Health into protocol development for our fasedienol program in social anxiety disorder, complementing our experience and existing datasets.”
Jayson Uffens, Co-Founder and Chief Technology Officer of GATC Health
“The hardest thing to get in drug development is a true outside read on your own assumptions”
Jayson Uffens, Co-Founder and Chief Technology Officer of GATC Health
“Vistagen knows these programs better than anyone. What we add is that independent perspective. Operon(®) looks at each candidate end-to-end: its chemistry, the biology it acts on, and how it’s likely to perform in people. Derisq(®) gives the team a second signal to test their thinking against as they plan the next studies. Their clinical judgment plus our predictive work is how these decisions should be made.”
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN) a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry, today announced its collaboration with GATC Health, a tech-bio company applying artificial intelligence and multiomics to drug discovery and development. The collaboration brings GATC Health’s proprietary Operon(®) platform and Derisq(®) report to Vistagen’s lead clinical-stage programs.
Through the collaboration, GATC Health uses its Operon(®) platform and Derisq(®) predictive intelligence capabilities to provide strategic insights for Vistagen’s potential next Phase 3 study of fasedienol for treatment of social anxiety disorder with the Liebowitz Social Anxiety Scale (LSAS) as the primary efficacy endpoint, as well as potential Phase 2 studies of itruvone for major depressive disorder and refisolone for menopausal hot flashes. Vistagen and GATC Health are now leveraging predictive modeling to complement traditional drug development approaches, providing deeper insights on complex scientific and development questions that impact protocol development, pipeline prioritization, and resource allocation.
Get started
Create a free account to read the full story.